Emergent BioSolutions (EBS) Amortization of Deferred Charges (2017 - 2026)

Emergent BioSolutions' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 21.74% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $9.3 million (up 232.14% YoY), while the FY2025 annual figure was $9.8 million, up 32.43% from the prior year.
• Amortization of Deferred Charges was $1.8 million for Q1 2026 at Emergent BioSolutions, down from $2.6 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $8.9 million in Q2 2023 to a low of -$6.7 million in Q3 2024.
• Historically, Amortization of Deferred Charges has averaged $2.6 million across 5 years, with a median of $2.3 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges surged 790.0% in 2023, then slumped 217.54% in 2024.
• A 5-year view of Amortization of Deferred Charges shows it stood at $1.0 million in 2022, then surged by 470.0% to $5.7 million in 2023, then sank by 61.4% to $2.2 million in 2024, then increased by 18.18% to $2.6 million in 2025, then plunged by 30.77% to $1.8 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $1.8 million (Q1 2026), $2.6 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.